| Go Back |


Christopher M. Overall

B.D.S., B.Sc. (Hons.), M.D.S., Ph.D., F.C.A.H.S., F.R.S.C.
Distinguished University Scholar,
Canada Research Chair Tier 1 Laureate in Protease Proteomics and Systems Biology,
Honorary Professor, Institute of Molecular Medicine and Cell Research, Albert-Ludwigs Universität Freiburg, DE,
Chair, Chromosome-Centric Human Proteome Project, HUPO
Send an e-mail
Website Lab

Rm: Life Sciences Centre 4.401
2350 Health Sciences Mall
Tel: 604-822-2958
Fax: 604-822-7742

Rm: Life Sciences Centre 4.420
2350 Health Sciences Mall
Tel: 604-822-3561
Fax: 604-822-7742

Research Areas:

Proteomics, degradomics, Human Proteome Project, proteases, Zoonotic Viruses, COVID-19, One Health, MMPs, anti-viral immunity, innate immunity

Teaching Areas:

Proteomics, degradomics, Human Proteome Project, connective tissue biochemistry and molecular biology,

BIOSKETCH November 2, 2023 
Professor Christopher Overall is a Full Professor, a Distinguished University Scholar, and Canada Research Chair Laureate in Protease Proteomics and Systems Biology at the University of British Columbia; an Honorary Professor at Albert-Ludwigs Universität Freiburg, Germany (2014–), and a Yonsei Distinguished Scholar of Yonsei University, Republic of Korea (2023–). He was a Senior Fellow of the Freiburg Institute of Advanced Studies, Albert-Ludwigs Universität Freiburg, Germany (2010–2013) and a Tier 1 Canada Research Chair in Protease Proteomics and Systems Biology (2001–2022). Dr Overall was inducted as a fellow into the Royal Society of Canada (FRASC) Academy of Science in 2018 and the Canadian Academy of Health Sciences (FCAHS) in 2005. 
Dr. Overall completed his B.D.S., Honours Science and Master’s degrees at the University of Adelaide, South Australia; his Ph.D. in Biochemistry at the University of Toronto, Canada; and was an MRC Centennial Fellow in his postdoctoral training with Dr. Michael Smith, Nobel Laureate, Biotechnology Laboratory, UBC. He launched his lab at UBC in 1993. On sabbatical in 1997 – 1998, he was a Senior Scientist at British Biotech Pharmaceuticals, Oxford, UK, and in 2004 and 2008, a Senior Scientist at the Expert Protease Platform, Centre for Proteomic Drug Discovery, Novartis Pharma, Basel, Switzerland. He is now a Creative Destruction Lab Scientist at the UBC Sauder School of Business, and a consultant for Genentech, Novartis and several Biotechnology companies. 
Chris is best known for his development of proteomic methodology for the discovery of protease substrates in vivo, thereby establishing the field of degradomics. He has used these techniques to reveal new biological roles for proteases in immunity and disease, most recently in the COVID-19 pandemic by SARS-CoV-2 proteases, as well as two new molecular correctors to cure MALT1 protease deficiency in a primary immunodeficiency, and now in One Health Strategies for investigation of viral zoonosis. By generating clinically relevant insights into how proteases dampen disease-fighting defense systems involved in inflammation and immunodeficiency, degradomics has revealed an unexplored layer of complexity in the hierarchy of cell and immune regulation, greatly adding to our understanding of protease function and drug targeting. 
He is a highly cited scientist (308 Career total, with an h-index = 105 and >39,300 citations—including 66 >100 – 199, 27 >200 – 499, 13 >500 – 999, 3 >1,000 – 1,500, and 1 >1,650, including 30 high-impact Nature (1), Science (2), Cell and daughter journal (27) papers, most as senior PI. He has disseminated his lab’s findings by > 266 keynote, plenary and invited talks at international and national conferences, and 236 invited seminars at universities, research institutes and companies. He has trained 40 postdoctoral fellows and graduated 14 Ph.D. and 6 M.Sc. students, with 20 now holding academic appointments: 9 are Full Professors (including 2 Department Chairs), 5 are Associate Professors, and 6 are Assist. Professors. Chris was awarded the UBC 2022 John McNeill Excellence in Health Research Mentorship Award. 
His peers elected Dr. Overall to organize and Chair the 2003 MMP and 2010 Protease Gordon Research Conferences, and in 2017 he was Co-Chair of the International Proteolysis Society Biannual Meeting, the premier conferences of his fields. He holds influential roles on the executive of >10 international committees, the most prominent of which was being elected to the Human Proteome Organization (HUPO) Executive Council and to Chair the HUPO Chromosome-centric Human Proteome Project (C-HPP). In 2022, he was invited to attend the G7 Research Summit on One Health to represent UBC. He is the recipient of numerous recognitions, e.g., election to the Royal Society of Canada; a Distinguished Scholar of UBC in 2023; a Yonsei Distinguished Scholar of Yonsei University (2023). He received the UBC 2006 Killam Faculty Research Prize; 2002 CIHR Researcher of the Year; and the Helmholtz Award (2008); International Proteolysis Society Lifetime Achievement Award (2011); Matrix Biology Society of Australia and New Zealand Barry Preston Award (2012); and the IADR Distinguished Scientist Award (2013). His advances in proteomics have been recognized by the Canadian National Proteomics Network Tony Pawson Award (2014); the Proteomass Scientific Society Award (2017); the 2018 Human Proteome Organization (HUPO) Discovery Award in Proteomics Sciences; and the 2022 Helmut Holzer Award. He is a Councillor of 1st -Hub Global Proteomics Project, Guangzhou, China. He has presented >277 keynote, plenary and invited talks at international and national conferences, and 240 invited seminars at universities, research institutes, and companies. 
Overall Laboratory Research Interests 
Professor Chris Overall is a biochemist and molecular biologist with internationally recognised expertise in proteases, proteomics, and inflammation signalling. Only 340/565 human proteases have known substrates and hence biological roles (Nature Reviews Genetics). Recognizing the importance of substrate-binding exosite domains on proteases, I led a team that was the first to use these as substrate ‘baits’ in a yeast two-hybrid screen, at a time when protein disulphide cross-linkages were predicted to exclude two-hybrid screens for extracellular proteins (Science). We showed that MMPs were ill-conceived drug targets as MMPs were tissue protective, in an era when MMPs have always been considered drug targets (Nature Reviews Drug Discovery), by orchestrating neutrophil and macrophage leukocyte responses through coordinate activation/inactivation of virtually all chemokines and complement. Recently we showed that macrophage MMP12 both stimulates, then over time inactivates, anti-viral interferon-α (Nature Medicine) and interferon-γ (Nature Communications), providing feedback which also drives the transition from pro-inflammatory IFN-γ-activated (M1) macrophages to tissue-reparative immunosuppressant (M2) macrophages. more details...